369 related articles for article (PubMed ID: 21334243)
21. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.
Macías M; Lanata CF; Zambrano B; Gil AI; Amemiya I; Mispireta M; Ecker L; Santos-Lima E
Pediatr Infect Dis J; 2012 Aug; 31(8):e126-32. PubMed ID: 22531237
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants.
Tregnaghi MW; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2011 Jun; 30(6):e88-96. PubMed ID: 21372751
[TBL] [Abstract][Full Text] [Related]
23. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants.
Madhi SA; Mitha I; Cutland C; Groome M; Santos-Lima E
Pediatr Infect Dis J; 2011 Apr; 30(4):e68-74. PubMed ID: 21289531
[TBL] [Abstract][Full Text] [Related]
26. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand.
Thisyakorn U; Chotpitayasunondh T; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):450-62. PubMed ID: 20578530
[TBL] [Abstract][Full Text] [Related]
28. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S
Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054
[TBL] [Abstract][Full Text] [Related]
29. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age.
Diaz-Mitoma F; Halperin SA; Tapiero B; Hoffenbach A; Zappacosta PS; Radley D; Bradshaw S; Martin JC; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2011 Feb; 29(6):1324-31. PubMed ID: 21134456
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of fully liquid DTaP₅-IPV-Hib compared with DTaP₃-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, 4, and 12 to 18 months of age: a phase III, single-blind, randomised, controlled, multicentre study.
Grimprel E; Wysocki J; Boisnard F; Thomas S; Mwawasi G; Reynolds D
Vaccine; 2011 Oct; 29(43):7370-8. PubMed ID: 21807056
[TBL] [Abstract][Full Text] [Related]
37. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
Prymula R; Kieninger D; Feroldi E; Jordanov E; B'Chir S; DaCosta X
Pediatr Infect Dis J; 2018 Aug; 37(8):823-830. PubMed ID: 29762363
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
[TBL] [Abstract][Full Text] [Related]
40. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
